Abbott Laboratories Corporation

Pharmacyclics, Inc.

Neonc Technologies, Inc.

S&b Pharma, Inc.

Abbvie Inc.

Symphony Evolution, Inc.

University of Southern California

Daniel A Dickman

Sanjay R Chemburkar

Michael D Wendt

Wang Shen

David John Augeri

Hong Ding

Sheela A Thomas

Hing L Sham

Daniel W Norbeck

Xiaoqi Chen

David A Betebenner

Daniel Levin

Rodger F Henry

David Lechuga-Ballesteros

Lawrence Kolaczkowski

Thomas R Herrin

Dale J Kempf

Thorsten K Oost

Xilu Wang

Aaron R Kunzer

Milan Bruncko

William J McClellan

Stephen W Fesik

Saul H Rosenberg

William Dvorak Shrader

Roopa Rai

Andrew M Petros

Steven M Hannick

Daniel J Plata

Jih-Hua Liu

Jurgen Dinges

Thomas C Chen

Steven Elmore

Bruce W Horrom

Howard E Morton

Yi-Yin Ku

Kieron E Wesson

William R Baker

Jien-Heh J Tien

M Robert Leanna

Satish Puppali

Stephen L Condon

Ketan M Patel

James J Fort

Arthur J Cooper

Eric J Stoner

William Porter

Patricia A Oliver

Gondi N Kumar

Yuping Niu

Philip J Hajduk

Jieh-Heh J Tien

Colin O'Bryan

Peter J Stengel

Steven A Baumeister

Dange Vijay Kumar

Satish Pupalli

David G Nettesheim

Juliette K Busse

Sriram Naganathan

James D Ratajczyk

Hormoz Mazdiyasni

Harry O Spiwek

Thomas M Zydowsky

Bhadra Shelat

Chi-nung W Hsiao

Emerich Eisenreich

Hemantkumar H Patel

David P Sawick

Ramesh R Patel

Brian A Roden

Mackenzie Marrs

John N Starr

JoAnn Wilson

David D Nettesheim

Steven W Elmore

David Augeri

William Mcclellan

Thorsten Oost

Thomas Chen

Crystalline Cannabidiol of a novel form, including (R,R)-(&#x2212;)-crystalline Cannabidiol, as well as methods of making such novel form of Cannabidiol, pharmaceutical formulations comprising such novel form of Cannabidiol, and methods of treating diseases with such novel form of Cannabidiol.

Crystalline form of cannabidiol

Solid cannabidivarin, crystalline cannabidivarin, (R,R)-(&#x2212;)-crystalline cannabidivarin, (S,S)-(+)-crystalline cannabidivarin and substantially pure forms thereof are disclosed herein. Further disclosed are methods of making such cannabidivarin, compositions and formulations comprising such cannabidivarin, and methods of treating disease with such cannabidivarin.

Crystalline cannabidivarin

The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Methods and devices for using isoperillyl alcohol

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

Factor VIIa inhibitor

New crystalline forms of lopinavir are disclosed.

Crystalline pharmaceutical

Magnesium salts/complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts/complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of cancer, arthritis, diseases related to angiogenesis, such as renal diseases, heart diseases, such as heart failure, atherosclerosis, and stroke, inflammation, ulcer, infertility, scleroderma, endometriosis, mesothelioma, and diabetes. In addition, methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role are provided.

Human ADAM-10 inhibitors

The present invention relates to biaryl carboxylic acid compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing these compounds and methods of treating diseases which express the Mcl-1 protein.

Biaryl carboxylic acid apoptosis promoters

A compound of the formula: is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Retroviral protease inhibiting compounds

N-Benzoyl arylsulfonamides having the formula are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.

N-acylsulfonamide apoptosis promoters

Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds and methods of treating diseases during which are expressed the Mcl-1 protein are disclosed.

Apoptosis promoters

N-Benzoyl arylsulfonamides having the formula are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.

Growing community of inventors

Longmont, CO, United States of America

Daniel A Dickman